NCT01195246View on ClinicalTrials.gov

Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

August 31, 2012

Conditions
End Stage Renal Disease
Interventions
BIOLOGICAL

HEPLISAV

Intramuscular (IM) injection on Day1

BIOLOGICAL

Engerix-B

Intramuscular (IM) injection on Day 1

BIOLOGICAL

Fendrix

Intramuscular (IM) injection on Day 1

Trial Locations (19)

Unknown

Aschaffenburg

Bamberg

Berlin

Cologne

Dresden

Düsseldorf

Essen

Halle

Hamburg

Hanover

Leipzig

Madgeburg

Mainz

Mannheim-Kafertal

München

Oberschleißheim

Rostock

Trier

Velbert

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY